drugset

drugset / Trial / NCT00224302

Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine

NCT00224302 ↗

Phase 4 Completed 20 enrolled Central Institute of Mental Health, Mannheim

Non-randomizedSingle-groupOpen-labelTreatment

Summary

We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders

Timeline

Start: 2005-08
Primary completion: 2007-11
Completion: 2007-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	—	—

Indications